We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Dunedin Income Growth Investment Trust Plc | DIG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.00 | 0.36% | 276.00 | 16:22:38 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 276.00 | 276.00 | 278.00 | 276.00 | 275.00 |
| Industry Sector |
|---|
| EQUITY INVESTMENT INSTRUMENTS |
| Top Posts |
|---|
Posted at 05/6/2024 19:50 by kiwi2007 Investors pull cash from ESG funds as performance lagsSustainably focused equity funds suffer net $40bn of outflows in 2024, the first sustained exodus Yes, I must admit that, in retrospect, I may have made a mistake investing here. |
Posted at 31/3/2019 20:14 by topvest A fairly steady trust. I've held for a few years and topped-up once I think. I'm happy to hold this golden oldie, until I become one!Read the 150 year booklet last year. A typical John Newlands booklet, but an interesting read. John Newlands seems to have a monopoly in the market for investment trust history publications... congratulations to him as investment trusts deserve a great deal more acclaim than they receive. Basically, investing in ten of the best investment trusts is all the average investor needs to do to secure a very robust financial future. Its been that way for well over 100 years! |
Posted at 03/1/2019 18:06 by topvest Aberdeen’s investment strategy as a quality value investor should start to work in their favour now. They have had a rubbish performance, versus growth investors. Growth is now officially a busted flush with all the secular leaders going down fast and in a bear market. FANG stocks, ASOS, Fevertree, most other highly rated stocks all about half way down from 2018 highs. Momentum gone and 50-80% declines await. Now is the time for Aberdeen to do well. If they don’t they have lost it. |
Posted at 23/12/2018 13:02 by escapetohome Im not an investor here, this trust was on my wathchlist, i pleased i held off. |
Posted at 23/12/2018 13:01 by escapetohome Yup, this doesnt seem right.Dunedin it manager, please pay more attention to timing of investments. It seems you rushed in on these investments , yes probably because you buy in bulk and there is not liquidity at really chrap prices, maybe. However, investors are noticing that you were way off the ball. |
Posted at 19/9/2018 10:51 by speedsgh from Fund Manager's Report in the latest Factsheet to 31/7/2018...The major share price movements within the portfolio were once again due to company specific events. French employee benefit and payments business Edenred increased sharply on the back of a very positive set of interim results, demonstrating the benefit of our overseas positioning in generating diverse and attractive investment opportunities. UK listed small cap life insurer Chesnara rebounded sharply on a broker upgrade that highlighted the significant discount to net assets and the attractive and growing dividend. Not owning Glencore also proved beneficial as the miner was hit by a potential US Department of Justice investigation into its conduct in a number of emerging markets. At a sector level oil companies lagged as hydrocarbon prices fell following a strong run since the start of the year amidst some concerns over rising US output. In contrast tobacco stocks continued to perform strongly, benefiting from solid results and a stronger dollar, partially reversing some of the very significant underperformance of the past twelve months. Pharmaceutical stocks also performed well primarily led by growing investor enthusiasm for AstraZeneca and their attractive revenue profile from new products. Activity remained relatively high as we continued to shift the portfolio towards better quality, higher growth and smaller companies. As a result we introduced new holdings in life sciences company Abcam and financial services provider London Stock Exchange. Both of these are lower yielding investments but offer the prospect of double digit dividend growth for many years ahead. Abcam is a world leading franchise specialising in the manufacture and distribution of antibodies used in scientific research. It has exceptional long–term growth prospects, a strong balance sheet and the potential to significantly increase their distributions to shareholders over time. London Stock Exchange has a very strong position in the provision of exchange, clearing, index and settlement services. This provides high and resilient levels of growth that should translate into attractive levels of dividend growth to its investors. We added further to positions in a number of mid-sized companies including Hansteen which owns a high yielding portfolio of industrial real estate, Assura the provider of primary care facilities across the UK and Aveva the leading design software provider for oil and gas, power and marine industries. At the larger end of the market cap spectrum we also increased our holding further in British American Tobacco, attracted by the elevated yield and resilient growth and National Grid where strong performance in their US assets increasingly underpins the high and steadily growing dividend. We trimmed our position in Experian given a stretched valuation following a significant increase in the share price on the back of positive results. We also exited our relatively small position in Swiss pharmaceutical giant Roche given lacklustre prospects for dividend growth and reduced our holding in HSBC where the growth outlook is also subdued and the yield no longer offers such an attractive premium to that achievable elsewhere. Our approach remains unchanged and we continue to focus on improving the medium term income and capital growth potential of the portfolio while maintaining appropriate diversity and balancing the near term requirements of our relatively high yield. Benefiting from the new combined research capabilities of the firm we have an increasingly full pipeline of attractive potential investments, particularly those focused toward capital and income growth. Finding higher yielding companies that we deem of sufficient quality for long-term investment is more challenging but we continue to evaluate a number of opportunities. All of which should allow us to position the portfolio in an increasingly differentiated manner, while underpinning the dividend policy. Equity markets remain relatively buoyant although there are a number of headwinds developing, particularly around global trade and the increasingly bellicose approach of the US to the implementation of sanctions on countries such as Turkey. As such we see little reason to shift from a conservative focus on higher quality businesses. While significant movements in large benchmark weighted stocks can affect near term relative performance, given changes to the portfolio and sound corporate performance we remain confident in the total return potential for the trust. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
